Lu Bin, Zhang Zhengquan
West China School of Pharmacy, Sichuan University, China.
J Pharm Sci. 2006 Dec;95(12):2619-30. doi: 10.1002/jps.20635.
To increase therapeutic efficiency of hydroxycamptothecin (HCPT) against colonic cancer and decrease its side-effects, highly dispersed HCPT was first incorporated in fast release microspheres. HCPT in the microspheres showed a solubility two times larger, and its cumulative release rate for 24 h in simulated colonic juice 140 times higher than that of free HCPT. The microspheres were then coated with a layer of Eudragit S100 by air suspension spray-drying method with a self-designed device to obtain colon-specific microspheres (HCPT-CSMS). The mean particle size of the microspheres was 200 microm before coating and 230 microm after coating. The in vitro cumulative release results for HCPT-CSMS in simulated gastric juice for 2 h, in simulated enteric juice for 4 h, and in simulated colonic juice for 18 h showed that over 60% of total HCPT released in simulated colonic juice in the initial 5 h. Animal tests with per os (po) administration showed that free HCPT was mainly absorbed in stomach and small intestine, while the HCPT in HCPT-CSMS was mainly delivered and absorbed in colon. po administration of HCPT-CSMS to nude mice with colonic cancer showed a cancer inhibition rate of 61.4% compared to 39.8% for free HCPT.
为提高羟基喜树碱(HCPT)对结肠癌的治疗效果并降低其副作用,首先将高度分散的HCPT载入速释微球中。微球中的HCPT溶解度增大了两倍,其在模拟结肠液中24小时的累积释放率比游离HCPT高140倍。然后通过自行设计的装置采用空气悬浮喷雾干燥法在微球表面包衣一层Eudragit S100,以获得结肠靶向微球(HCPT-CSMS)。包衣前微球的平均粒径为200微米,包衣后为230微米。HCPT-CSMS在模拟胃液中2小时、模拟肠液中4小时以及模拟结肠液中18小时的体外累积释放结果表明,在最初5小时内,总HCPT中有超过60%在模拟结肠液中释放。经口(po)给药的动物试验表明,游离HCPT主要在胃和小肠吸收,而HCPT-CSMS中的HCPT主要在结肠递送和吸收。给荷结肠癌裸鼠经口给予HCPT-CSMS,其抑癌率为61.4%,而游离HCPT为39.8%。